纳晶微针联合米诺地尔酊治疗男性雄激素性秃发的临床疗效  

Clinical efficacy of nanocrystalline needles combined with 5%minoxidil tincture in treatment of androgenetic alopecia in male

作　　者：魏盛[1] 朱敏刚[1] 王音[1] 李军[1] 胡晓波[1] 曹雯勤 陆维敏 Wei Sheng;Zhu Mingang;Wang Yin;Li Jun;Hu Xiaobo;Cao Wenqin;Lu Weimin(Department of Dermatology,the First People’s Hospital of Jiashan,Jiashan 314100,China)

机构地区：[1]浙江省嘉善县第一人民医院皮肤科,314100

出　　处：《中华医学美学美容杂志》2020年第5期372-374,共3页Chinese Journal of Medical Aesthetics and Cosmetology

摘　　要：目的探讨纳晶微针联合5%米诺地尔酊对男性雄激素性秃发的疗效。方法2016年6月至2018年6月,浙江省嘉善县第一人民医院皮肤科将60例(18~47岁)男性雄激素性秃发患者分为试验组与对照组各30例,对照组单纯外用5%米诺地尔酊治疗,试验组在外用5%米诺地尔酊基础上加用纳晶微针治疗,每周治疗2次,每次10 min,6个月进行疗效判定。结果试验组有效24例,有效率80.00%,对照组16例,有效率53.30%,两组比较差异有统计学意义(χ^2=6.507,P<0.05)。皮肤镜下观察>20%毛发直径变细、毳毛增多、局部无毛征、黄点征等各项指标的改善,试验组均优于对照组,差异有统计学意义(均P<0.05)。结论纳晶微针联合5%米诺地尔酊治疗雄激素性秃发安全、有效,推荐临床应用。Objective To study the clinical efficacy of nanocrystalline needles combined with 5% minoxidil tincture in the treatment of androgenetic alopecia of male.Methods A total of 60 patients with androgenetic alopecia were randomly divided into treatment group and control group,with 30 patients in each group.The control group was treated with 5% minoxidil tincture 2 times a day.On the basis of the control group,the treatment group was treated with nanocrystalline needles combined with 5% minoxidil tincture for 10 minutes 2 times a week.The clinical effects of different treatments were compared after six months.Results There was a significant difference in overall response rate between the treatment group and the control group(80.00%vs.53.30%,P<0.05).The improvement of the each clinical features of image by dermoscopy in patients with hair loss disease included more than 20% of hair diameter diminish,vellus hair increased,partly acomia and yellow dot sign had a significant difference between the treatment group and the control group(P<0.05).Conclusion Nanocrystalline needles combined with 5%minoxidil tincture has a good clinical effect in the treatment of androgenetic alopecia.

关 键 词：秃发 米诺地尔酊 治疗结果 纳晶微针 雄激素性秃发 

分 类 号：R758.71[医药卫生—皮肤病学与性病学]